Healthy
Conditions
Brief summary
This is a randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Akkermansia muciniphila Akk11 in healthy adult.
Interventions
DIETARY_SUPPLEMENTProbiotic
The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
DIETARY_SUPPLEMENTMaltodextrin
The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
Sponsors
Wecare Probiotics Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or Female subject age 18-60 years at screening. 2. Healthy subject according to investigator judgement based on screening data. 3. Subjects must be either of non-childbearing potential, or if of childbearing potential, they must be abstinent or have practiced adequate contraception for the entire study. 4. Subjects who have not smoked in the past 1 month prior to screening. 5. Subjects with a healthy and balanced diet, including adequate fiber intake in their food consumption. 6. Subject or subject's legally acceptable representatives have the ability to comply with the trial protocol. 7. Signed informed consent from the subject or subject's legally acceptable representatives (must be obtained before any trial related activities).
Exclusion criteria
1. History of or presence of diabetes, immunodeficiency disorders, or chronic illness. 2. Regular use of medications known to affect the gastrointestinal system or alter gut microbiota composition, including but not limited to antibiotics, and immunosuppressants. 3. Have continuous, daily use of probiotics or probiotic containing products within 1 month prior to randomization. 4. Pregnant, planning a pregnancy or lactating female (urinary pregnancy test will be applied to female subjects at screening). 5. Change type of diet during study. 6. Any known allergy or intolerance to any of the ingredients in the formulation of the product under study. 7. History of drug, alcohol or other substance abuse, or other factors that limit their ability to cooperate during the study. 8. History of or presence of eating disorder. 9. Subject whose condition does not make them eligible to the study, according to the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in stool quality | 30 days | Stool consistency (using the Bristol Stool Scale) from baseline to day 30. The Bristol Stool Scale is a tool to assess gut health by classifying feces into seven categories based on shape and consistency: types 1-2 indicate constipation, 3-4 are normal, and 5-7 suggest diarrhea. |
Countries
Indonesia
Contacts
Primary ContactVicky Achmad Ginanjar, bachelor
Backup ContactNatalina Soesilawati, Dr
Outcome results
None listed